Levocarnitine injection-Dosage and administration
declares having received honoraria from Novo Nordisk, Eli Lilly, Akebia Therapeutics, Ardelyx, Becton Dickinson, Endologix, FibroGen, GSK, Medtronic, Neovasc, Provention Bio, ReCor, BrainStorm Cell Therapeutics, Alnylam and Intarcia for consulting activities, and research funding to his institution from AbbVie, Esperion, AstraZeneca, CSL Behring, Novartis and Eli Lilly
According to CMS billing guidance (Medicare Article A57755), the primary covered indications are pernicious anemia, documented cobalamin deficiency with laboratory evidence, and malabsorption syndromes that prevent adequate oral B12 absorption
For a broader overview of how these therapies work, see how GLP-1 actually supports weight loss